Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease

Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease

Among those with moderate-to-advanced chronic kidney disease, the relationship between blood pressure and cardiovascular disease appears ‘U’-shaped, but is loglinear in apparently healthy adults. The Study of Heart and Renal Protection randomized 9270 patients with chronic kidney disease to simvasta...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون:	Herrington, W, Staplin, N, Judge, P, Mafham, M, Emberson, J, Haynes, R, Wheeler, D, Walker, R, Tomson, C, Agodoa, L, Wiecek, A, Lewington, S, Reith, C, Landray, M, Baigent, C
التنسيق:	Journal article
منشور في:	American Heart Association 2016

مواد مشابهة

Use of causal diagrams to inform the analysis and interpretation of observational studies: An example from the Study of Heart and Renal Protection (SHARP)
حسب: Staplin, N, وآخرون
منشور في: (2016)

Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP).
حسب: Haynes, R, وآخرون
منشور في: (2014)

Evaluating the contribution of the cause of kidney disease to prognosis in ckd: Results from the Study of Heart and Renal Protection (SHARP)
حسب: Haynes, R, وآخرون
منشور في: (2014)

Conventional and genetic evidence on the association between adiposity and chronic kidney disease
حسب: Zhu, P, وآخرون
منشور في: (2020)

Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
حسب: Storey, B, وآخرون
منشور في: (2017)

Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)
حسب: Herrington, WG, وآخرون
منشور في: (2023)

Evidence for the prevention and treatment of stroke in dialysis patients
حسب: Herrington, W, وآخرون
منشور في: (2014)

Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank
حسب: Zhu, P, وآخرون
منشور في: (2020)

A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease
حسب: Schlackow, I, وآخرون
منشور في: (2017)

Impact of diabetes on the effects of sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
حسب: Herrington, W, وآخرون
منشور في: (2022)

Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection.
حسب: Mafham, M, وآخرون
منشور في: (2017)

Effects of lowering LDL cholesterol on progression of kidney disease.
حسب: Haynes, R, وآخرون
منشور في: (2014)

Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
حسب: Mayne, K, وآخرون
منشور في: (2024)

Cost-effectiveness of lowering LDL cholesterol with statins and ezetimibe in chronic kidney disease
حسب: Mihaylova, B, وآخرون
منشور في: (2019)

Conventional and genetic evidence on the association between adiposity and CKD
حسب: Zhu, P, وآخرون
منشور في: (2020)

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: Results from the study of heart and renal protection
حسب: Reith, C, وآخرون
منشور في: (2017)

Benefits of lowering cholesterol in chronic kidney disease Reply
حسب: Baigent, C, وآخرون
منشور في: (2011)

Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial
حسب: Mayne, KM, وآخرون
منشور في: (2024)

Neprilysin inhibition in chronic kidney disease.
حسب: Judge, P, وآخرون
منشور في: (2014)

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection
حسب: C. Reith, وآخرون
منشور في: (2017-05-01)

Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD
حسب: Lamprea-Montealegre, J, وآخرون
منشور في: (2019)

Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial
حسب: Haynes, R, وآخرون
منشور في: (2018)

Determining the relationship between blood pressure, kidney function, and chronic kidney disease: insights from genetic epidemiology
حسب: Staplin, N, وآخرون
منشور في: (2022)

Effects of empagliflozin on fluid overload, weight and blood pressure in chronic kidney disease
حسب: Mayne, K, وآخرون
منشور في: (2023)

Cystatin C and risk of vascular and nonvascular mortality: a prospective cohort study of older men.
حسب: Emberson, JR, وآخرون
منشور في: (2010)

Biliary tract and liver complications in polycystic kidney disease
حسب: Judge, P, وآخرون
منشور في: (2017)

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
حسب: Staplin, N, وآخرون
منشور في: (2023)

Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP)
حسب: Staplin, N, وآخرون
منشور في: (2015)

The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection.
حسب: Herrington, W, وآخرون
منشور في: (2014)

Which cardiovascular risk factors matter in chronic kidney disease?
حسب: Baigent, C, وآخرون
منشور في: (2007)

Estimated glomerular filtration rate and the risk of major vascular events and all-cause mortality: a meta-analysis.
حسب: Mafham, M, وآخرون
منشور في: (2011)

Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.
حسب: Haynes, R, وآخرون
منشور في: (2014)

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
حسب: Herrington, W, وآخرون
منشور في: (2018)

Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy
حسب: Storey, B, وآخرون
منشور في: (2018)

Fibroblast growth factor-23 and risk of cardiovascular diseases: a Mendelian randomization study
حسب: Donovan, K, وآخرون
منشور في: (2022)

Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease
حسب: Zhu, D, وآخرون
منشور في: (2025)

Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials
حسب: Staplin, N, وآخرون
منشور في: (2021)

Chronic kidney disease, heart failure and neprilysin inhibition
حسب: Haynes, R, وآخرون
منشور في: (2019)

Smoking and adverse outcomes in patients With CKD: the Study of Heart and Renal Protection (SHARP)
حسب: Emberson, J, وآخرون
منشور في: (2016)

Comparison of routinely collected data with clinical trial adjudicated direct follow-up: post-hoc analyses of serious cardiovascular events from the United Kingdom-based ASCEND randomized trial
حسب: Harper, C, وآخرون
منشور في: (2021)